Related Experiment Videos
The therapy of benign myoclonic epilepsy in infants
1Department of Neuropediatrics, Children's Hospital, Medical Academy Carl Gustav Carus, Dresden, Germany.
Epilepsy Research. Supplement
|January 1, 1992
Insights
Valproate monotherapy effectively treated benign myoclonic epilepsy in most patients, achieving seizure control or significant reduction. Thrombocytopenia was the sole observed side effect in this study.
Area of Science:
- Neurology
- Clinical Medicine
Background:
- Benign myoclonic epilepsy is a specific epilepsy syndrome.
- Effective treatment options are crucial for managing seizure disorders.
Purpose of the Study:
- To evaluate the efficacy and tolerability of valproate monotherapy in patients with benign myoclonic epilepsy.
Main Methods:
- A cohort of 14 patients diagnosed with benign myoclonic epilepsy was treated with valproate monotherapy.
- Patient outcomes, including seizure control and frequency, were monitored.
- Adverse events were recorded to assess tolerability.
Main Results:
- Valproate monotherapy resulted in complete seizure control in 10 out of 14 patients.
- Three additional patients experienced a distinct reduction in seizure frequency.
- Thrombocytopenia was identified as the only side effect during the study.
Conclusions:
- Valproate monotherapy demonstrates high efficacy in treating benign myoclonic epilepsy.
- The treatment is generally well-tolerated, with thrombocytopenia being the primary adverse event.
- Valproate is a viable therapeutic option for benign myoclonic epilepsy management.
Abstract:
The authors report the results of treatment of 14 patients (10 male, 4 female, average age 20.3 years) with benign myoclonic epilepsy. Valproate monotherapy led to control of seizures in 10 cases, and to a distinct reduction of seizure frequency in 3 cases. Thrombocytopenia was the only side-effect encountered in this study.